Letter to the Editor
Reply to Letter to the Editor: “Critical Appraisal of Isorhamnetin as a Candidate for Pulmonary Arterial Hypertension Treatment”
1Department of Internal and Pediatrics, School of Clinical Medicine, Qilu Medical University, Zibo, Shandong, China